

## New Vaccines and Novel Monoclonal Antibody Treatments on the Frontline of COVID-19

Resource	Address
<b>Amanat F, Krammer F.</b> SARS-CoV-2 vaccines: Status report. <i>Immunity</i> . 2020;52:583-589.	<a href="https://pubmed.ncbi.nlm.nih.gov/32259480/">https://pubmed.ncbi.nlm.nih.gov/32259480/</a>
<b>Baden LR, et al.</b> Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. <i>N Engl J Med</i> . 2021;384:403-416.	<a href="https://www.nejm.org/doi/full/10.1056/nejmoa2035389">https://www.nejm.org/doi/full/10.1056/nejmoa2035389</a>
<b>Baum A, et al.</b> Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. <i>Science</i> . 2020;369:1014-1018.	<a href="https://pubmed.ncbi.nlm.nih.gov/32540904/">https://pubmed.ncbi.nlm.nih.gov/32540904/</a>
<b>Castelli MS, et al.</b> The pharmacology and therapeutic applications of monoclonal antibodies. <i>Pharmacol Res Perspect</i> . 2019;7:e00535.	<a href="https://pubmed.ncbi.nlm.nih.gov/31859459/">https://pubmed.ncbi.nlm.nih.gov/31859459/</a>
<b>Centers for Disease Control and Prevention (CDC).</b> CDC Recommends Use of Johnson & Johnson's Janssen COVID-19 Vaccine Resume. <b>Updated May 6, 2021.</b>	<a href="https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/JJUpdate.html">https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/JJUpdate.html</a>
<b>Centers for Disease Control and Prevention (CDC).</b> COVID Data Tracker. <b>Accessed July 2, 2021.</b>	<a href="https://covid.cdc.gov/covid-data-tracker/#datatracker-home">https://covid.cdc.gov/covid-data-tracker/#datatracker-home</a>
<b>Centers for Disease Control and Prevention (CDC).</b> Health Equity. <b>Accessed July 2, 2021.</b>	<a href="https://www.cdc.gov/coronavirus/2019-ncov/community/health-equity/index.html">https://www.cdc.gov/coronavirus/2019-ncov/community/health-equity/index.html</a>
<b>Centers for Disease Control and Prevention (CDC).</b> SARS-CoV-2 Variant Classifications and Definitions. <b>Updated June 29, 2021.</b>	<a href="https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html">https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html</a>
<b>Gandhi RT, et al.</b> Mild or moderate Covid-19. <i>N Engl J Med</i> . 2020;383:1757-1766.	<a href="https://pubmed.ncbi.nlm.nih.gov/32329974/">https://pubmed.ncbi.nlm.nih.gov/32329974/</a>
<b>Gottlieb RL, et al.</b> Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: A randomized clinical trial. <i>JAMA</i> . 2021;325:632-644.	<a href="https://pubmed.ncbi.nlm.nih.gov/33475701/">https://pubmed.ncbi.nlm.nih.gov/33475701/</a>
<b>Hansen J, et al.</b> Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. <i>Science</i> . 2020;369:1010-1014.	<a href="https://pubmed.ncbi.nlm.nih.gov/32540901/">https://pubmed.ncbi.nlm.nih.gov/32540901/</a>
Infectious Disease Society of America (IDSA). <b>IDSA Guidelines on the Treatment and Management of Patients with COVID-19.</b> Last updated June 25, 2021.	<a href="https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/">https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/</a>
Infectious Disease Society of America (IDSA). <b>Vaccines &amp; Immunity.</b> Accessed July 2, 2021.	<a href="https://www.idsociety.org/covid-19-real-time-learning-network/vaccines/vaccines/#Phase3">https://www.idsociety.org/covid-19-real-time-learning-network/vaccines/vaccines/#Phase3</a>
National Institutes of Health (NIH) Community Engagement Alliance. <b>Resources to Share.</b> Accessed July 2, 2021.	<a href="https://covid19community.nih.gov/communication-resources">https://covid19community.nih.gov/communication-resources</a>
National Institutes of Health (NIH). <b>Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.</b> Accessed July 2, 2021.	<a href="https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf">https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf</a>

National Institutes of Health (NIH). <b>COVID-19 Vaccination Communication: Applying Behavioral and Social Science to Address Vaccine Hesitancy and Foster Vaccine Confidence.</b> Accessed July 2, 2021.	<a href="https://obsr.od.nih.gov/wp-content/uploads/2020/12/COVIDReport_Final.pdf">https://obsr.od.nih.gov/wp-content/uploads/2020/12/COVIDReport_Final.pdf</a>
Polack FP, et al. <b>Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.</b> <i>N Engl J Med.</i> 2020;383:2603-2615.	<a href="https://www.nejm.org/doi/full/10.1056/nejmoa2034577">https://www.nejm.org/doi/full/10.1056/nejmoa2034577</a>
RADx-UP. <b>Community Resources.</b> Accessed July 2, 2021.	<a href="https://radx-up.org/learning-resources/">https://radx-up.org/learning-resources/</a>
Sadoff J, et al. <b>Interim results of a phase 1–2a trial of Ad26.COV2.S Covid-19 vaccine.</b> <i>N Engl J Med.</i> 2021;384(19):1824-1835.	<a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2034201">https://www.nejm.org/doi/full/10.1056/NEJMoa2034201</a>
Starr TN, et al. <b>Prospective mapping of viral mutations that escape antibodies used to treat COVID-19.</b> <i>Science.</i> 2021;371:850-854.	<a href="https://pubmed.ncbi.nlm.nih.gov/33495308/">https://pubmed.ncbi.nlm.nih.gov/33495308/</a>
US Food and Drug Administration (FDA). Fact Sheet for Health Care Providers. <b>Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab.</b> Revised May 14, 2021.	<a href="https://www.fda.gov/media/145802/download">https://www.fda.gov/media/145802/download</a>
US Food and Drug Administration (FDA). Fact Sheet for Health Care Providers. <b>Emergency Use Authorization (EUA) of Casirivimab and Imdevimab.</b> Revised December 2020.	<a href="https://www.fda.gov/media/143892/download">https://www.fda.gov/media/143892/download</a>
US Food and Drug Administration (FDA). Fact Sheet for Health Care Providers. <b>Emergency Use Authorization (EUA) of Sotrovimab.</b> Issued May 2021.	<a href="https://www.fda.gov/media/149534/download">https://www.fda.gov/media/149534/download</a>
Walsh EE, et al. <b>Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates.</b> <i>N Engl J Med.</i> 2020;383:2439-2450.	<a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2027906">https://www.nejm.org/doi/full/10.1056/NEJMoa2027906</a>
Wang P, et al. <b>Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.</b> <i>Nature.</i> 2021;593(7857):130-135.	<a href="https://pubmed.ncbi.nlm.nih.gov/33684923/">https://pubmed.ncbi.nlm.nih.gov/33684923/</a>
Wang W, et al. <b>Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China.</b> <i>J Med Virol.</i> 2020;92:441-447.	<a href="https://pubmed.ncbi.nlm.nih.gov/31994742/">https://pubmed.ncbi.nlm.nih.gov/31994742/</a>
Wang Y, et al. <b>Kinetics of viral load and antibody response in relation to COVID-19 severity.</b> <i>J Clin Invest.</i> 2020;130:5235-5244.	<a href="https://pubmed.ncbi.nlm.nih.gov/32634129/">https://pubmed.ncbi.nlm.nih.gov/32634129/</a>
Weinreich DM, et al. <b>REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19.</b> <i>N Engl J Med.</i> 2021;384:238-251.	<a href="https://pubmed.ncbi.nlm.nih.gov/33332778/">https://pubmed.ncbi.nlm.nih.gov/33332778/</a>
Widge AT, et al. <b>Durability of responses after SARS-CoV-2 mRNA-1273 vaccination.</b> <i>N Engl J Med.</i> 2021;384:80-82.	<a href="https://www.nejm.org/doi/full/10.1056/NEJMc2032195">https://www.nejm.org/doi/full/10.1056/NEJMc2032195</a>